S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58

Arcturus Therapeutics (ARCT) Stock Forecast, Price & News

+1.20 (+7.24%)
(As of 05/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
488,044 shs
Average Volume
671,682 shs
Market Capitalization
$469.48 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Arcturus Therapeutics logo

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.


Arcturus Therapeutics Tops Q1 EPS by 338c
Arcturus Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$16.19 per share


Net Income
$-203.70 million
Net Margins
Pretax Margin




Free Float
Market Cap
$469.48 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.10 out of 5 stars

Medical Sector

475th out of 1,418 stocks

Pharmaceutical Preparations Industry

207th out of 677 stocks

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

Is Arcturus Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view top-rated stocks.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,050,000 shares, an increase of 24.0% from the April 15th total of 2,460,000 shares. Based on an average daily trading volume, of 602,100 shares, the days-to-cover ratio is presently 5.1 days. Currently, 13.4% of the shares of the stock are sold short.
View Arcturus Therapeutics' Short Interest

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Arcturus Therapeutics

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Monday, May, 9th. The biotechnology company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.44) by $0.50. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 64.94% and a negative net margin of 1,282.62%. During the same period last year, the company earned ($2.15) earnings per share.
View Arcturus Therapeutics' earnings history

What price target have analysts set for ARCT?

7 analysts have issued 1-year price objectives for Arcturus Therapeutics' stock. Their forecasts range from $17.00 to $105.00. On average, they anticipate Arcturus Therapeutics' stock price to reach $42.38 in the next twelve months. This suggests a possible upside of 138.5% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcturus Therapeutics' key executives?
Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 50, Pay $950k)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 43, Pay $640k)
  • Mr. Andrew H. Sassine MBA, CFO & Director (Age 58, Pay $640k)
  • Mr. Lance Kurata, Chief Legal Officer
  • Dr. Steven George Hughes M.B.A., M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board (Age 54, Pay $664k)
  • Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller
  • Dr. Dushyant B. Varshney Ph.D., Exec. VP & Chief Technology Officer
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Kelly A. Lindert M.D., Chief Devel. Officer of Vaccines
What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (14.24%), State Street Corp (12.18%), ARK Investment Management LLC (9.04%), BlackRock Inc. (6.42%), Sumitomo Mitsui Trust Holdings Inc. (5.32%) and Nikko Asset Management Americas Inc. (5.31%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics

Which major investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including ACT Capital Management LLC, ARK Investment Management LLC, Citigroup Inc., BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Jane Street Group LLC, Connor Clark & Lunn Investment Management Ltd., and JPMorgan Chase & Co.. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Arcturus Therapeutics stock?

ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, UBS Group AG, Federated Hermes Inc., Integral Health Asset Management LLC, Los Angeles Capital Management LLC, Nikko Asset Management Americas Inc., and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, and Keith C Kummerfeld.
View insider buying and selling activity for Arcturus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $17.77.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics has a market capitalization of $469.48 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203.70 million in net income (profit) each year or ($7.53) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

Arcturus Therapeutics employs 177 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 900-2660 or via email at [email protected].

This page was last updated on 5/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.